Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;24(2S1):S176-S265.
doi: 10.1016/j.ajt.2024.01.014.

OPTN/SRTR 2022 Annual Data Report: Liver

Affiliations
Free article

OPTN/SRTR 2022 Annual Data Report: Liver

Allison J Kwong et al. Am J Transplant. 2024 Feb.
Free article

Abstract

In 2022, liver transplant activity continued to increase in the United States, with an all-time high of 9,527 transplants performed, representing a 52% increase over the past decade (2012-2022). Of these transplants, 8,924 (93.7%) were from deceased donors and 603 (6.3%) were from living donors. Liver transplant recipients were 94.5% adult and 5.5% pediatric. The overall size of the liver transplant waiting list contracted, with more patients being removed than added, although 10,548 adult patients still remained on the waiting list at the end of 2022. Alcohol-associated liver disease continued to be the leading diagnosis among both candidates and recipients, followed by metabolic dysfunction-associated steatohepatitis. Simultaneous liver-kidney transplant was the most common multiorgan combination, with 800 liver-kidney transplants performed in 2022; in addition, there were 303 new listings for kidney transplant via the safety net mechanism. Among adults added to the liver waiting list in 2021, 39.9% received a deceased donor liver transplant within 3 months; 45.7%, within 6 months; and 54.5%, within 1 year. Pretransplant mortality decreased to 12.3 deaths per 100 patient-years in 2022, although still 15.6% of removals from the waiting list were for death or being too sick for transplant. Graft and patient survival outcomes after deceased donor liver transplant improved, approximating pre-COVID-19 pandemic levels, with 5.1% mortality observed at 6 months; 6.8%, at 1 year; 12.7%, at 3 years; 19.8%, at 5 years; and 35.7%, at 10 years. Five-year graft and patient survival rates after living donor liver transplant exceeded those of deceased donor liver transplant. Candidates receiving model for end-stage liver disease exception points for hepatocellular carcinoma constituted 15.5% of transplants performed in 2022, with similar transplant rates and posttransplant outcomes compared to cases without hepatocellular carcinoma exception. In 2022, more pediatric liver transplant candidates were added to the waiting list and underwent transplant compared with either of the preceding 2 years, with an uptick in living donor liver transplant volume. Although pretransplant mortality has improved after the recent policy change prioritizing pediatric donors for pediatric recipients, still, in 2022, 50 children died or were removed from the waiting list for being too sick to undergo transplant. Posttransplant mortality among pediatric liver transplant recipients remained notable, with death occurring in 4.0% at 6 months, 6.0% at 1 year, 8.2% at 3 years, 9.8% at 5 years, and 13.9% at 10 years. Similar to adult living donor recipients, pediatric living donor recipients had better 5-year patient survival compared with deceased donor recipients.

Keywords: Allocation; distribution; liver transplant; waiting list.

PubMed Disclaimer

Similar articles

  • OPTN/SRTR 2021 Annual Data Report: Liver.
    Kwong AJ, Ebel NH, Kim WR, Lake JR, Smith JM, Schladt DP, Schnellinger EM, Handarova D, Weiss S, Cafarella M, Snyder JJ, Israni AK, Kasiske BL. Kwong AJ, et al. Am J Transplant. 2023 Feb;23(2 Suppl 1):S178-S263. doi: 10.1016/j.ajt.2023.02.006. Am J Transplant. 2023. PMID: 37132348
  • OPTN/SRTR 2020 Annual Data Report: Kidney.
    Lentine KL, Smith JM, Hart A, Miller J, Skeans MA, Larkin L, Robinson A, Gauntt K, Israni AK, Hirose R, Snyder JJ. Lentine KL, et al. Am J Transplant. 2022 Mar;22 Suppl 2:21-136. doi: 10.1111/ajt.16982. Am J Transplant. 2022. PMID: 35266618
  • OPTN/SRTR 2021 Annual Data Report: Kidney.
    Lentine KL, Smith JM, Miller JM, Bradbrook K, Larkin L, Weiss S, Handarova DK, Temple K, Israni AK, Snyder JJ. Lentine KL, et al. Am J Transplant. 2023 Feb;23(2 Suppl 1):S21-S120. doi: 10.1016/j.ajt.2023.02.004. Am J Transplant. 2023. PMID: 37132350 Free PMC article.
  • OPTN/SRTR 2018 Annual Data Report: Liver.
    Kwong A, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Noreen SM, Foutz J, Miller E, Snyder JJ, Israni AK, Kasiske BL. Kwong A, et al. Am J Transplant. 2020 Jan;20 Suppl s1:193-299. doi: 10.1111/ajt.15674. Am J Transplant. 2020. PMID: 31898413 Review.
  • OPTN/SRTR 2018 Annual Data Report: Lung.
    Valapour M, Lehr CJ, Skeans MA, Smith JM, Uccellini K, Goff R, Foutz J, Israni AK, Snyder JJ, Kasiske BL. Valapour M, et al. Am J Transplant. 2020 Jan;20 Suppl s1:427-508. doi: 10.1111/ajt.15677. Am J Transplant. 2020. PMID: 31898416 Review.

Cited by

LinkOut - more resources